FDA Seeks 10% Increase In Biden’s FY 2024 Budget, Proposes Enhancing Regulatory Authorities
The FDA has requested $7.2 billion as part of the president’s fiscal year 2024 budget, $128.2 million of which the…
Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births
Privately held-Covis Pharma, the maker of Makena (hydroxyprogesterone caproate injection) to reduce the risk of preterm birth, said…
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer ‘Tranq’ Or ”Zombie Drug’
The FDA issued an “import alert” about the animal tranquilizer xylazine, also called “tranq,” “tranq dope,” and “zombie drug.” The…
Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine
https://www.dailymail.co.uk/health/article-11772327/Man-CURED-HIV-D-sseldorf-patient-virus-free.html?ito=social-twitter_mailonline
https://www.nature.com/articles/s41591-023-02213-x
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer’s Drug
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi. </
SAVA, LLY, IBB: Why These Alzheimer’s Related Stocks Are Volatile On Friday
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to
Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Meta Platforms, This Biotech ETF And These China Plays Are CNBC’s ‘Final Trades’
The iShares Biotechnology ETF (NASDAQ: IBB), which includes several large cap biotechs, has recently narrowed its year-to-date loss to aroun